Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study

Liver International

Volumn 36, Issue 8, 2016, Pages 1108-1115

  Park, Jun Yong ^a,b   Kim, Chang Wook ^b,c   Bae, Si Hyun ^b,d   Jung, Kyu Sik ^a,b   Kim, Hee Yeon ^b,c   Yoon, Seung Kew ^b,d   Han, Kwang Hyub ^a,b   Ahn, Sang Hoon ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Center   (South Korea)

^c Uijeongbu St Mary's Hospital   (South Korea)

^d The Catholic University of Korea   (South Korea)

Author keywords

chronic hepatitis B; combination therapy; entecavir; multidrug resistant; tenofovir

Indexed keywords

ADEFOVIR; CLEVUDINE; CREATININE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; PEGINTERFERON; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS B; CREATININE BLOOD LEVEL; DRUG TREATMENT FAILURE; DYSPEPSIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEPATITIS B VIRUS; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; THORAX PAIN;

EID: 84978884037     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13059     Document Type: Article

References (25)

1. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335–52.
2. Kim BK, Revill PA, Ahn SH. HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther 2011; 16: 1169–86.
3. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531–61.
4. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167–85.
5. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661–2.
6. Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol 2012; 56: S112–22.
7. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503–14.
8. Marcellin P, Gane EJ, Flisiak R, et al. Long term treatment with tenofovir disoproxil fumarate for CHB infection is safe and well tolerated and associated with durable virologic response with no detectable resistance. Hepatology 2014; 60 (Suppl. 1): Abstract 229.
9. Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis 2012; 12: 341–53.
10. Petersen J, Ratziu V, Buti M, et al. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol 2012; 56: 520–6.
11. Lee YB, Lee JH, Lee DH, et al. Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains. Antimicrob Agents Chemother 2014; 58: 6710–6.
12. Lee JM, Ahn SH, Chang HY, et al. Reappraisal of HBV genotypes and clinical significance in Koreans using MALDI-TOF mass spectrometry. Korean J Hepatol 2004; 10: 260–70.
13. Han KH, Hong SP, Choi SH, et al. Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B. Antivir Ther 2011; 16: 77–87.
14. Berg T, Marcellin P, Zolium F, et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 2010; 139: 1207–17.
15. Patterson SJ, George J, Strasser SI, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011; 60: 247–54.
16. Son CY, Ryu HJ, Lee JM, et al. Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir. Liver Int 2012; 32: 1179–85.
17. Peters MG, Hann HH, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91–101.
18. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307–13.
19. Fung S, Kwan P, Fabri M, et al. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2014; 146: 980–8.
20. Lim YS, Yoo BC, Byun KS, et al. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. Gut 2016; 65: 1042–51.
21. Lim YS, Byun KS, Yoo BC, et al. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. Gut 2016; 65: 852–60.
22. Qi X, Xiong S, Yang H, Miller M, Delaney WE. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007; 12: 355–62.
23. Tan J, Degertekin B, Wong SN, et al. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008; 48: 391–8.
24. Yim HJ, Hwang SG. Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade. Clin Mol Hepatol 2013; 19: 195–209.
25. Kim MN, Lee CK, Ahn SH, et al. Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy. Liver Int 2014; 34: 1543–9.